KEY CHARACTERISTICS • Manufactured at four ISO 13485 certified sites, providing global consistency and increased security of supply • Documented change control beyond CAS number level, reducing risk of change • Non-phthalate and formulated without animal-derived substances • Different tones of amber available on request —more or less red or yellow and/or lighter or darker • Also available in liquid form REGULATORY SUPPORT • Pre-tested raw materials: - ISO 10993-1 and USP parts (Class VI) - European Pharmacopeia, monograph 3.1.15, USP and elemental analysis as per ICH Q3D - USP criteria appearance of solution, color • Registered Drug Master File (Type III) by the FDA • Food contact compliance established with FDA/EU* • YBB00102002-2015 (oral liquid pharmaceutical PET bottles) compliance support APPLICATION BULLETIN * FDA/EU compliance information available upon request Healthcare use limitations apply—see below.

• Any action that may be taken at a meeting of the Committee may be taken by written consent so long as the written consent is unanimously approved and filed with the Corporate Secretary. • The Company’s Senior Vice President, Global Operations and Process Improvement or his/her designee, will be the management liaison to the Committee. • The Committee may appoint subcommittees from time to time as needed, and may delegate authority to such subcommittees or to officers of the Company when appropriate, consistent with applicable laws, regulations and listing standards. • The Corporate Secretary or his/her designee shall be responsible for keeping minutes of the Committee meetings. • The Committee will meet at least two times a year and at such other times as may be requested by its Chair. 3 • The Committee will annually review its charter and recommend any changes to the Governance and Corporate Responsibility Committee.

ga_5ZFGRMWVZK*MTczMTMzNDQ3Mi4yLjEuMTczMTMzNDQ4OC40NC4wLjA avient.com/contact-0 https://www.avient.com/sites/default/files/2023-01/GlasArmor%20Ballistic%20Resistant%20Panels%20Case%20Study.pdf

Dose rate can be linked to online viscometer to correct the dose rate to compensate for variations in PCR feed IV.

SEC Filings

The list below provides links to pdf files for Avient's ISO Certifications (ISO Certificates).

Any prices presented by Seller are net prices, i.e. do not include the value added tax, and net prices will be increased by an appropriate value added tax, customs duties and excise tax (if any), the cost of which will be covered by Buyer. Taxes, Fees, and Duties. Buyer will reimburse Seller for all federal, state, provincial, local or other taxes (other than income taxes), excises or charges, including environmental remedial taxes and fees, which Seller must pay in connection with the manufacture and supply of Product, but only those amounts not already included in the price at the issuance of order confirmation by Seller.

 Factors that could cause actual results to differ materially from those implied by these forward-looking statements include, but are not limited to:  The final amount of charges resulting from the planned North American asset realignment and the Company’s ability to realize anticipated savings and operational benefits from the asset realignment;  Our ability to achieve the strategic and other objectives relating to the acquisition of Spartech Corporation, including any expected synergies;  Our ability to successfully integrate Spartech and achieve the expected results of the acquisition, including, without limitation, the acquisition being accretive;  Disruptions, uncertainty or volatility in the credit markets that could adversely impact the availability of credit already arranged and the availability and cost of credit in the future;  The financial condition of our customers, including the ability of customers (especially those that may be highly leveraged and those with inadequate liquidity) to maintain their credit availability;  The speed and extent of an economic recovery, including the recovery of the housing market;  Our ability to achieve new business gains;  The effect on foreign operations of currency fluctuations, tariffs, and other political, economic and regulatory risks;  Changes in polymer consumption growth rates in the markets where we conduct business;  Changes in global industry capacity or in the rate at which anticipated changes in industry capacity come online;  Fluctuations in raw material prices, quality and supply and in energy prices and supply;  Production outages or material costs associated with scheduled or unscheduled maintenance programs;  Unanticipated developments that could occur with respect to contingencies such as litigation and environmental matters;  An inability to achieve or delays in achieving or achievement of less than the anticipated financial benefit from initiatives related to working capital reductions, cost reductions, employee productivity goals, and an inability to raise or sustain prices for products or services;  An inability to raise or sustain prices for products or services;  An inability to maintain appropriate relations with unions and employees;  The inability to achieve expected results from our acquisition activities;  Our ability to continue to pay cash dividends;  The amount and timing of repurchases of our common shares, if any; and  Other factors affecting our business beyond our control, including, without limitation, changes in the general economy, changes in interest rates and changes in the rate of inflation.  The above list of factors is not exhaustive.  We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise. The non-GAAP financial measures include: adjusted EPS, earnings before interest, tax, depreciation and amortization (EBITDA), adjusted EBITDA, net debt, Specialty platform operating income, Specialty platform gross margin percentage, adjusted operating income, return on invested capital, net debt/ EBITDA, and the exclusion of corporate charges in certain calculations.

Esteja ciente de que esta Declaração de Privacidade não se aplica a esses file:///C:/Users/jalmeida/AppData/Roaming/iManage/Work/Recent/Avient%20do%20Brasil%20Ltda.%20_%20Consultoria%20em%20Proteção%20de%20Dados/Formulário%20de%20Solicitação%20de%20Acesso%20ao%20Titular%20de%20Dados sites. A data da última revisão desta Declaração de Privacidade file:///C:/Users/jalmeida/AppData/Roaming/iManage/Work/Recent/Avient%20do%20Brasil%20Ltda.%20_%20Consultoria%20em%20Proteção%20de%20Dados/Formulário%20de%20Solicitação%20de%20Acesso%20ao%20Titular%20de%20Dados file:///C:/Users/jalmeida/AppData/Roaming/iManage/Work/Recent/Avient%20do%20Brasil%20Ltda.%20_%20Consultoria%20em%20Proteção%20de%20Dados/Formulário%20de%20Solicitação%20de%20Acesso%20ao%20Titular%20de%20Dados está indicada no topo da página. Asia Sales Office file:///C:/Users/jalmeida/AppData/Roaming/iManage/Work/Recent/Avient%20do%20Brasil%20Ltda.%20_%20Consultoria%20em%20Proteção%20de%20Dados/Formulário%20de%20Solicitação%20de%20Acesso%20ao%20Titular%20de%20Dados mailto:Lgpd@avient.com file:///C:/Users/jalmeida/AppData/Roaming/iManage/Work/Recent/Avient%20do%20Brasil%20Ltda.%20_%20Consultoria%20em%20Proteção%20de%20Dados/Formulário%20de%20Solicitação%20de%20Acesso%20ao%20Titular%20de%20Dados file:///C:/Users/jalmeida/AppData/Roaming/iManage/Work/Recent/Avient%20do%20Brasil%20Ltda.%20_%20Consultoria%20em%20Proteção%20de%20Dados/Formulário%20de%20Solicitação%20de%20Acesso%20ao%20Titular%20de%20Dados Innovation Center Manufacturing Plant Regional Headquarters Shanghai, China 2F, Block C 200 Jinsu Road Pudong, 201206 Declaração de Privacidade Introdução Pontos Principais 1.

Page 102 Critical Imperatives – Medium to Long Term • Continue cultural and paradigm shift from commodity compounder to collaborative formulator as One PolyOne • Accelerate innovation and leverage megatrends to improve our mix of business with higher-margin improve our mix of business with higher-margin specialty products • Increase specialty contribution and advance globalization via acquisitions • Drive relentless execution and creative innovation as key competitive differentiators Page 103 2011 Proforma ColorMatrix 2015 Target “Where we are” “Where we expect to be” 1) Operating Income % Specialty 8.9% PP&S 7.2% 12 – 16% 9 – 12% Elevating our Expectations and Yours PP&S 7.2% Distribution 5.6% 2) Specialty Platform % of Operating Income 50% 3) ROIC* (after-tax) 10% 4) Adjusted Annual EPS Growth 3 yr CAGR = 71% 9 – 12% 6 – 7.5% 65 – 75% 15% Double Digit Expansion *ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period Page 104